Supplemental table 1: αvβ3, αvβ5 and αvβ6 integrin expression in correlation with tissue based and clinical characteristics

αvβ3 / αvβ5 / αvβ6
Bimodal expression / Median H-score (range) / Bimodal expression / Median H-score (range) / Bimodal expression / Median H-score (range)
Present / Absent / Present / Absent / Present / Absent
Histology
Non-squamous / 13/139 (9.4%) / 126/139 (90.6%) / 0 (0-80) / 26/139 (18.7%) / 113/139 (81.3%) / 0 (0-150) / 81/139 (41.7%) / 58/139 (41.7%) / 20 (0-300)
Squamous / 0/31 (0.0%) / 31/31 (100.0%) / 0 (0-0) / 7/31 (22.6%) / 24/31 (77.4%) / 0 (0-40) / 16/31 (51.6%) / 15/31 (48.4%) / 10 (0-300)
SCLC / 0/19 (0.0%) / 19/19 (100.0%) / 0 (0-0) / 1/19 (5.3%) / 18/19 (94.7%) / 0 (0-180) / 5/19 (26.3%) / 14/19 (73.7%) / 0 (0-60)
Median Ki67 proliferation index (range) / 28.4%
(13-77%) / 41.4%
(2-87%) / 45.4%
(15-77%) / 40.6%
(2-87%) / 36.6%
(3-87%) / 46.3%
(2-86%)
Median HIF1 index (range) / 97
(25-211) / 60
(0-270) / 90
(0-230) / 60
(0-270) / 60
(0-250) / 60
(0-270)
Microvascular density (range) / 80
(0-230) / 73
(7-298) / 75
(16-183) / 73
(7-298) / 71
(16-298) / 79
(7-180)
Number of BM
1 / 11/133 (8.3%) / 122/133 (91.7%) / 0 (0-80) / 25/133 (18.8%) / 108/133 (81.2%) / 0 (0-150) / 75/133 (56.4%) / 58/133 (43.6%) / 20 (0-300)
2-3 / 1/42 (2.4%) / 41/42 (97.6%) / 0 (0-20) / 6/42 (14.3%) / 36/42 (85.7%) / 0 (0-180) / 18/42 (42.9%) / 24/42 (57.1%) / 0 (0-300)
>3 / 1/16 (6.2%) / 15/16 (93.8%) / 0 (0-10) / 4/16 (25.0%) / 12/16 (75.0%) / 0 (0-90) / 10/16 (62.5%) / 6/16 (37.5%) / 10 (0-180)
Status of extracranial metastases
Present / 1/34 (2.9%) / 33/34 (97.1%) / 0 (0-80) / 7/34 (20.6%) / 27/34 (79.4%) / 0 (0-150) / 19/34 (55.9%) / 15/34 (44.1%) / 10 (0-300)
Absent / 12/157 (7.6%) / 145/157 (92.4%) / 0 (0-10) / 28/157 (17.8%) / 129/157 (82.2%) / 0 (0-180) / 84/157 (53.5%) / 73/157 (46.5%) / 25 (0-300)
Brain only metastatic site
Yes / 5/78 (6.4%) / 73/78 (93.6%) / 0 (0-80) / 16/104 (15.4%) / 88/104 (84.6%) / 0 (0-140) / 56/104 (53.8%) / 48/104 (46.2%) / 10 (0-300)
No / 8/104 (7.7%) / 96/104 (92.3%) / 0 (0-60) / 18/78 (23.1%) / 60/78 (76.9%) / 0 (0-180) / 43/78 (55.1%) / 35/78 (44.9%) / 15 (0-300)
Localization of BM
Supratentorial / 11/124 (8.9%) / 113/124 (91.1%) / 0 (0-80) / 26/124 (21.0%) / 98/124 (79.0%) / 0 (0-140) / 66/124 (53.2%) / 58/124(46.8%) / 10 (0-300)
Infratentorial / 2/65 (3.1%) / 63/65 (96.9%) / 0 (0-40) / 9/65 (13.8%) / 56/65 (86.2%) / 0 (0-180) / 36/65 (55.4%) / 29/65 (44.6%) / 10 (0-300)
Prior irradiation
Yes / 2/10 (20.0%) / 8/10 (80.0%) / 0 (0-20) / 0/10 (0.0%) / 10/10 (100.0%) / 0 (0-0) / 4/10 (40.0%) / 6/10 (60.0%) / 0 (0-120)
No / 11/177 (6.2%) / 166/177 (93.8%) / 0 (0-80) / 35/177 (19.8%) / 142/177 (80.2%) / 0 (0-180) / 97/177 (54.8%) / 80/177 (45.2%) / 10 (0-300)
CNS recurrence
Yes / 5/84 (6.0%) / 79/84 (94.0%) / 0 (0-80) / 12/84 (14.3%) / 72/84 (85.7%) / 0 (0-180) / 44/84 (52.4%) / 40/84 (47.6%) / 10 (0-300)
No / 1/97 (7.2%) / 90/97 (92.8%) / 0 (0-60) / 22/97 (22.7%) / 75/97 (77.3%9 / 0 (0-140) / 54/97 (55.7%) / 43/97 (44.3%) / 10 (0-300)

Supplemental table 2: αvβ3, αvβ5 and αvβ6 integrin expression in tumor cells, endothelia cells and tumor stroma

αvβ3 / αvβ5 / αvβ6
Present / Absent / Present / Absent / Present / Absent
Brain metastases
Tumor cells / 13/191 (6.8%) / 178/191 (93.2%) / 35/191 (18.3%) / 156/191 (81.7%) / 103/191 (53.9%) / 88/191 (46.1%)
Endothelial cells / 130/191 (68.1%) / 61/191 (31.9%) / 167/191 (87.4%) / 24/191 (12.6%) / 0/191 (0.0%) / 191/191 (100.0%)
Stroma / 2/191 (1.0%) / 189/191 (99.0%) / 151/191 (79.1%) / 40/191 (20.9%) / 0/191 (0.0%) / 191/191 (100.0%)
Primary tumor
Tumor cells / 1/18 (5.6%) / 17/18 (94.4%) / 3/16 (18.8%) / 13/18 (81.3%) / 12/18 (66.7%) / 6/18 (33.3%)
Endothelial cells / 1/18 (5.6%) / 17/18 (94.4%) / 15/16 (93.8%) / 1/16 (6.3%) / 0/18 (0.0%) / 18/18 (100.0%)
Stroma / 0/18 (0.0%) / 18/18 (100.0%) / 15/16 (93.8%) / 1/16 (6.3%) / 0/18 (0.0%) / 18/18 (100.0%)

*Bold values indicate significant correlation